9:00 – 10:15am Session #1:Healthcare reform – progress to date – challenges ahead

• Professor Mark Pauly, PhD – Pattern of beneficiary cost-sharing at different income levels that can facilitate protection from financial catastrophe and likely improved health outcomes
• Joel White, former Staff Director HW&M Subcommittee on health (Medicare Part D, HIPPA) – Federal executive branch and Congressional action toward implementation of PPACA, and further action needed.   HIT implementation issues.
• Kip Piper, High level state health & Medicaid policy executive, and leading MCO consultant - Implementation of state health insurance exchanges, and MCO movement to enter exchanges in 2014
• Sarah Collins, President America’sHealth – Key aspects of PPACA implementation - evidence-based strategies to improve outcomes for costly chronic conditions, provider shortages and solutions
  

10:15-10:45am                          Coffee Break/Networking

10:45am – 12:00pm Concurrent Session #2:Innovation in Healthcare - devices, diagnostics, and the use of comparative effectiveness

• Angel Medical, Andrew Taylor, CFO, Angel-Medical – implantable ischemic monitoring device technology for high risk repeat MI patients – challenges being faced by regulatory agencies and payers – how AngelMed has and is overcoming them
• Comparative effectiveness (CE) – Harlan Weisman, MD, Chief Science & Technology officer, Medical Devices and Diagnostics,  Johnson & Johnson, member Patient Centered Outcomes Research Institute Board of Governors –– funding/programs being rolled out on CE – how comparative effectiveness may affect innovation
• How will Medicare use comparative effectiveness in assessing new technologies?  Steve Phurrough, MD, MPA
• Use of CE to drive payer coverage & payment – Jeff Voigt, case study: orthopedic implants – is more expensive always better for the patient and for the system?  An examination of recent CE publications in leading orthopedic journals by the author.
• Tessarae Inc. – Klaus Schafer, MD, MPH, CEO molecular diagnostic test for infectious diseases and for rare diseases – how Tessarae is building its business despite onerous regulatory challenges in the US
  

10:45am – 12:00pm Concurrent Session #2:Creation of innovative healthcare delivery systems in the era of health reform
In an era of capital constraint, not-for-profit hospital systems have sought private equity funding to not only support strategic capital needs but to
finance acquisition growth plans as well.  The lines between not-for-profit and for profit hospital operations continue to blur.  Hear from two industry leaders on their transformational deals with private equity firms.  The panelists will address the following topics: their evaluation process for embarking on the transaction, the selection process for the right partner, and finally, how their current organization is best prepared to accommodate health reform and the tailwinds ahead in the industry.

• Mark GirardMD, MBA Senior Vice President and President, Steward Healthcare
• Leo Brideau, President and CEO, Ascension Healthcare
• Moderator: Maureen Spivack – banking deal/trends/perspectives

12:00-1:15pm  Lunch with Keynote Speaker: Stuart Diamond, Wharton Professor – How to Negotiate to Achieve Your Goals in the Real World.  Includes book signing.    8th Floor Huntsman Hall

1:15-2:30pm Concurrent Session #2: Financing healthcare innovations – perspectives from PE, VC, investment bankers – where would you put your money and why?

• Commentary / analysis of returns by sector.  What’s realistic?
• What types / sizes of funds are attracting LPs?
• How are firms structuring their funds and personnel based on impending changes?
• How are financing vehicles being structured for investment in technologies/companies?
• Are the covenants in the deals being structured differently than before?
• Investment horizons – are they different and why?
  

Late state investments (IPOs, PIPEs): Ali Behbahani, MD, NEA

Traditional venture:  Ash Khanna, SV Life Sciences - SV has raised one of the largest life science only funds in the past year, and is actively investing in early/mid stage across the life sciences

Investment Banker:  Andy Weisenfeld, MTS Partners [invited] - MTS has recently been working on private placements (investments in venture backed companies), business spinouts (from big biotechs), PIPEs of newly public life science companies, and traditional M&A

Adjunct Wharton Faculty:  Gary Kurtzman MD

1:15-2:30pm Concurrent Session #2: Healthcare  informatics:
In the aftermath of the ARRA and Health Care Reform, health IT continues to be an instrumental component in healthcare policy, as the federal government invests $42 billion into its infrastructure.   Hear from this distinguished group of Healthcare leaders to gain greater insight into health IT as the key ingredient for the needed innovation around delivery and improvement of care for individuals and populations.

• What is the real progress to date? - Doug Arnold WG’84, CEO, Medical Professional Services
• In what ways has IT helped stakeholders within one community address the complex needs of  high risk population – Christy Stephenson, EVP, Catholic Health East, New Jersey
• IT fueling innovation & altering care at the consumer level  – Jordan Goldberg,  CEO, sticKK
• Bryan Bushick, WG’89 moderator
  

2:30-3:00pm                                  Coffee Break/Networking

3:00-4:15pm Closing Session: Healthcare 2020 – what will our healthcare system look like in 2020?
Putting it all together – a debate

• Paul Howard, PhD – can we afford current bill?
• Ezekiel Emanuel, MD, PhD - PPACA is affordable and the right way to go!
• We can afford the current bill! [speaker to be identified]
• Jonathan Bush, MBA, Chairman & CEO, athenahealth – can we afford the current bill? – private industry perspective
• Bill Winkenwerder, MD, MBA, Moderator
  
  

 4:30-6:00pm                    Cocktail Reception